Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03877055 · ClinicalTrials.gov registry record · Phase 1
A Study of Copanlisib and Ibrutinib in Mantle Cell Lymphoma
A Phase 1 study, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 8
- Enrollment target
NCT03877055: Completed Phase 1 study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT03877055 is a Phase 1 study that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 8 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03877055, a Phase 1 study, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 8 participants
- Enrollment target
Study Summary
The purpose of this study is to test the safety and any good and bad side effects of combining 2 study drugs, copanlisib and ibrutinib. This combination of drugs could shrink your Mantle Cell Lymphoma (MCL), but it could also cause side effects. Both these drugs have been given to people before, but this is the first time that they are being given together.
Interventions
- DRUG Ibrutinib
- DRUG Copanlisib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2019-03-13 |
| Est. Completion | 2022-10-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03877055
The ClinicalTrials.gov registry entry for NCT03877055 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Ibrutinib is the first listed.
NCT03877055 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03877055 about?
NCT03877055 is a clinical study titled "A Study of Copanlisib and Ibrutinib in Mantle Cell Lymphoma". The purpose of this study is to test the safety and any good and bad side effects of combining 2 study drugs, copanlisib and ibrutinib. This combination of drugs could shrink your Mantle Cell Lymphoma (MCL), but it could also cause side effects. Both these drugs have been given to people before, but...
What is the current status of trial NCT03877055?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2019-03-13. Estimated completion is 2022-10-07.
What interventions are being tested in trial NCT03877055?
The interventions under investigation include: Ibrutinib (DRUG), Copanlisib (DRUG).
Who is sponsoring clinical trial NCT03877055?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.